Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dermata Therapeutics, Inc. (DRMA)
USD1.30
-0.02 (-1.52%)
US NASDAQ Healthcare Biotechnology
Address
3525 Del Mar Heights Road 92130
San Diego, CA, US
San Diego, CA, US
CEO
Gerald T. Proehl
Website
dermatarx.com
IPO
2021-08-13
CIK 1853816 ISIN US2498455045
Also trades on
NASDAQ Capital Market · DRMA (USD)
NASDAQ Capital Market · DRMAW (USD)
Description
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.30
-0.02 (-1.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
73.1K
Beta
0.69
Float Shares
498.5K
Free Float %
73.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.03% | -4.80% | -8.46% | -7.75% | -62.10% | -48.71% | +52.66% | -96.93% | -99.90% | -99.90% | -99.90% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
1.30
Low
6.00
+361.5%
Consensus
6.00
+361.5%
Median
6.00
+361.5%
High
6.00
+361.5%
DCF (Unlevered)
8,120.94
+624,587.6%
DCF (Levered)
8,121.40
+624,623.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
6.00
+361.5%
|
Quality scores
Altman Z-Score
-15.68
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+89.8% ★ Q1'26: +89.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+505.4% Q1'26: +648.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
—
|
—
|
100.0K
100.0K – 100.0K
|
750.0K
750.0K – 750.0K
+650.0% YoY
|
| EBITDA |
-12.29M
|
-7.77M
|
—
— – —
|
—
— – —
|
| EBIT |
-12.29M
|
-7.77M
|
—
— – —
|
—
— – —
|
| Net Income |
-12.29M
est: -22.61M (+45.7%)
|
-7.56M
est: -7.41M (-2.0%)
|
-2.04M
-2.04M – -2.04M
+72.5% YoY
|
-1.38M
-1.38M – -1.38M
+32.3% YoY
|
| SGA |
4.31M
|
4.84B
|
—
— – —
|
—
— – —
|
| EPS |
-80.32
est: -147.80 (+45.7%)
|
-8.16
est: -8.00 (-2.0%)
|
-2.20
-2.20 – -2.20
+72.5% YoY
|
-1.49
-1.49 – -1.49
+32.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
9
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gerald T. Proehl | 3.33M | 39.20% | — | — | — | — | IN | Delaware | 2021-08-27 | ↗ |
| 2 | Proehl Investment Ventures LLC | 2.93M | 34.20% | — | — | — | — | OO | Cayman Islands | 2021-08-27 | ↗ |
| 3 | David Hale | 623.3K | 7.50% | — | — | — | — | IN | Delaware | 2021-08-27 | ↗ |
| 4 | Hale BioPharma Ventures LLC | 536.0K | 6.40% | — | — | — | — | OO | Cayman Islands | 2021-08-27 | ↗ |
| 5 | Armistice Capital, LLC | 412.1K | 9.99% | — | 412.1K | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 6 | Steven Boyd | 412.1K | 9.99% | — | 412.1K | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 7 | Mitchell P. Kopin | 143.9K | 4.99% | — | — | — | 68.4K | HC, IN | United States America | 2023-06-01 | ↗ |
| 8 | Daniel B. Asher | 143.9K | 4.00% | — | — | — | — | HC, IN | United States America | 2023-06-01 | ↗ |
| 9 | Intracoastal Capital LLC | 143.9K | 4.00% | — | 143.9K | — | 68.4K | OO | United States America | 2023-06-01 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
19
Sells
0
Shares acquired
2.41M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+2,411,470
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-17 | Bedoya-Toro Munera Maria E | Officer | P-Purchase | A | Common Stock | 1,000 | 1.27 | 1.3K | 1,012 | D | ↗ |
| 2026-01-02 | WIERENGA WENDELL | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 2.18 | 5.5K | 2,500 | D | ↗ |
| 2026-01-02 | Van Hoose Kyri K. | Officer | A-Award | A | Stock Option (right to buy) | 18,000 | 2.18 | 39.2K | 18,000 | D | ↗ |
| 2026-01-02 | Scott Kathleen D. | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 2.18 | 5.5K | 2,500 | D | ↗ |
| 2026-01-02 | Sandler Andrew Seth | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 2.18 | 5.5K | 2,500 | D | ↗ |
| 2026-01-02 | PROEHL GERALD T | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 37,500 | 2.18 | 81.8K | 37,500 | D | ↗ |
| 2026-01-02 | Nardo Christopher J. | Officer | A-Award | A | Stock Option (right to buy) | 18,000 | 2.18 | 39.2K | 18,000 | D | ↗ |
| 2026-01-02 | Mento Steven J | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 2.18 | 5.5K | 2,500 | D | ↗ |
| 2026-01-02 | HALE DAVID F | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 2.18 | 5.5K | 2,500 | D | ↗ |
| 2026-01-02 | FISHER MARY | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 2.18 | 5.5K | 2,500 | D | ↗ |
| 2026-01-02 | Bradrick Brittany | Director | A-Award | A | Stock Option (Right to Buy) | 2,500 | 2.18 | 5.5K | 2,500 | D | ↗ |
| 2026-01-02 | Bedoya-Toro Munera Maria E | Officer | A-Award | A | Stock Option (right to buy) | 9,000 | 2.18 | 19.6K | 9,000 | D | ↗ |
| 2025-12-23 | Van Hoose Kyri K. | Officer | A-Award | A | Warrant (Right to Buy) | 7,874 | 2.04 | 16.1K | 7,874 | D | ↗ |
| 2025-12-23 | PROEHL GERALD T | Director / Officer / 10% Owner | A-Award | A | Series C Warrant (Right to Buy) | 490,196 | 2.04 | 1,000.0K | 490,496 | I | ↗ |
| 2025-01-23 | HALE DAVID F | Director | A-Award | A | Common Stock | 78,741 | 0.00 | — | 80,957 | I | ↗ |
| 2025-01-21 | Van Hoose Kyri K. | Officer | A-Award | A | Common Stock | 78,741 | 0.00 | — | 78,741 | D | ↗ |
| 2025-01-21 | PROEHL GERALD T | Director / Officer / 10% Owner | A-Award | A | Common Stock | 787,402 | 0.00 | — | 799,508 | I | ↗ |
| 2025-01-21 | HALE DAVID F | Director | A-Award | A | Warrant (Right to Buy) | 78,741 | 1.27 | 100.0K | 78,741 | I | ↗ |
| 2025-01-21 | FISHER MARY | Director | A-Award | A | Warrant (Right to Buy) | 196,851 | 1.27 | 250.0K | 196,851 | D | ↗ |
| 2025-01-13 | WIERENGA WENDELL | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 1.38 | 6.9K | 5,000 | D | ↗ |
| 2025-01-13 | Van Hoose Kyri K. | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 1.38 | 27.6K | 20,000 | D | ↗ |
| 2025-01-13 | Scott Kathleen D. | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 1.38 | 6.9K | 5,000 | D | ↗ |
| 2025-01-13 | Sandler Andrew Seth | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 1.38 | 6.9K | 5,000 | D | ↗ |
| 2025-01-13 | PROEHL GERALD T | Director / Officer | A-Award | A | Stock Option (right to buy) | 45,000 | 1.38 | 62.1K | 45,000 | D | ↗ |
| 2025-01-13 | Nardo Christopher J. | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 1.38 | 27.6K | 20,000 | D | ↗ |
| 2025-01-13 | Mento Steven J | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 1.38 | 6.9K | 5,000 | D | ↗ |
| 2025-01-13 | HALE DAVID F | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 1.38 | 6.9K | 5,000 | D | ↗ |
| 2025-01-13 | FISHER MARY | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 1.38 | 6.9K | 5,000 | D | ↗ |
| 2025-01-13 | Bradrick Brittany | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 1.38 | 6.9K | 5,000 | D | ↗ |
| 2025-01-13 | Bedoya-Toro Munera Maria E | Officer | A-Award | A | Stock Option (right to buy) | 8,000 | 1.38 | 11.0K | 8,000 | D | ↗ |
| 2024-01-04 | WIERENGA WENDELL | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.61 | 6.1K | 10,000 | — | ↗ |
| 2024-01-04 | Van Hoose Kyri K. | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.61 | 30.5K | 50,000 | — | ↗ |
| 2024-01-04 | Scott Kathleen D. | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.61 | 6.1K | 10,000 | — | ↗ |
| 2024-01-04 | Sandler Andrew Seth | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.61 | 6.1K | 10,000 | — | ↗ |
| 2024-01-04 | PROEHL GERALD T | Director / Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 0.61 | 76.2K | 125,000 | — | ↗ |
| 2024-01-04 | Nardo Christopher J. | Officer | A-Award | A | Stock Option (right to buy | 50,000 | 0.61 | 30.5K | 50,000 | — | ↗ |
| 2024-01-04 | Mento Steven J | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.61 | 6.1K | 10,000 | — | ↗ |
| 2024-01-04 | HALE DAVID F | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.61 | 6.1K | 10,000 | — | ↗ |
| 2024-01-04 | FISHER MARY | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.61 | 6.1K | 10,000 | — | ↗ |
| 2024-01-04 | Bradrick Brittany | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.61 | 6.1K | 10,000 | — | ↗ |
| 2024-01-04 | Bedoya-Toro Munera Maria E | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 0.61 | 15.2K | 25,000 | — | ↗ |
| 2023-01-03 | Van Hoose Kyri K. | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2023-01-03 | Nardo Christopher J. | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2023-01-03 | Bedoya-Toro Munera Maria E | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-10-06 | WIERENGA WENDELL | Director | A-Award | A | Common Stock | 20,654 | 0.00 | — | 62,398 | — | ↗ |
| 2022-10-06 | Scott Kathleen D. | Director | A-Award | A | Common Stock | 11,359 | 0.00 | — | 27,145 | — | ↗ |
| 2022-10-06 | Sandler Andrew Seth | Director | A-Award | A | Common Stock | 10,120 | 0.00 | — | 24,184 | — | ↗ |
| 2022-10-06 | HALE DAVID F | Director | A-Award | A | Common Stock | 30,155 | 0.00 | — | 75,720 | — | ↗ |
| 2022-10-06 | FISHER MARY | Director | A-Award | A | Common Stock | 9,810 | 0.00 | — | 23,443 | — | ↗ |
| 2022-10-06 | Bradrick Brittany | Director | A-Award | A | Common Stock | 9,810 | 0.00 | — | 23,443 | — | ↗ |
| 2022-07-07 | WIERENGA WENDELL | Director | A-Award | A | Common Stock | 18,110 | 0.00 | — | 41,744 | — | ↗ |
| 2022-07-07 | Scott Kathleen D. | Director | A-Award | A | Common Stock | 9,960 | 0.00 | — | 15,786 | — | ↗ |
| 2022-07-07 | Sandler Andrew Seth | Director | A-Award | A | Common Stock, par value $0.0001 per share | 8,874 | 0.00 | — | 14,064 | — | ↗ |
| 2022-07-07 | HALE DAVID F | Director | A-Award | A | Common Stock | 26,441 | 0.00 | — | 45,565 | — | ↗ |
| 2022-07-07 | FISHER MARY | Director | A-Award | A | Common Stock | 8,602 | 0.00 | — | 13,633 | — | ↗ |
| 2022-07-07 | Bradrick Brittany | Director | A-Award | A | Common Stock, par value $0.0001 per share | 8,602 | 0.00 | — | 13,633 | — | ↗ |
| 2022-07-01 | Nardo Christopher J. | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-04-07 | WIERENGA WENDELL | Director | A-Award | A | Common Stock | 10,593 | 0.00 | — | 15,471 | — | ↗ |
| 2022-04-07 | Scott Kathleen D. | Director | A-Award | A | Common Stock | 5,826 | 0.00 | — | 5,826 | — | ↗ |
| 2022-04-07 | Sandler Andrew Seth | Director | A-Award | A | Common Stock, par value $0.0001 per share | 5,190 | 0.00 | — | 5,190 | — | ↗ |
| 2022-04-07 | HALE DAVID F | Director | A-Award | A | Common Stock | 15,466 | 0.00 | — | 19,124 | — | ↗ |
| 2022-04-07 | FISHER MARY | Director | A-Award | A | Common Stock | 5,031 | 0.00 | — | 5,031 | — | ↗ |
| 2022-04-07 | Bradrick Brittany | Director | A-Award | A | Common Stock, par value $0.0001 per share | 5,031 | 0.00 | — | 5,031 | — | ↗ |
| 2022-01-12 | Bradrick Brittany | Director | A-Award | A | Stock Option (right to Buy) | 10,000 | 1.50 | 15.0K | 10,000 | — | ↗ |
| 2022-01-03 | WIERENGA WENDELL | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 1.88 | 9.4K | 5,000 | — | ↗ |
| 2022-01-03 | Van Hoose Kyri K. | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 1.88 | 56.4K | 30,000 | — | ↗ |
| 2022-01-03 | Scott Kathleen D. | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 1.88 | 9.4K | 5,000 | — | ↗ |
| 2022-01-03 | Sandler Andrew Seth | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 1.88 | 9.4K | 5,000 | — | ↗ |
| 2022-01-03 | PROEHL GERALD T | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 4,517 | 2.07 | 9.3K | 4,517 | — | ↗ |
| 2022-01-03 | Nardo Christopher J. | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 1.88 | 56.4K | 30,000 | — | ↗ |
| 2022-01-03 | Mento Steven J | Director | A-Award | A | Stock Option (right to Buy) | 5,000 | 1.88 | 9.4K | 5,000 | — | ↗ |
| 2022-01-03 | HALE DAVID F | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 1.88 | 9.4K | 5,000 | — | ↗ |
| 2022-01-03 | FISHER MARY | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 1.88 | 9.4K | 5,000 | — | ↗ |
| 2022-01-03 | Bedoya-Toro Munera Maria E | Officer | A-Award | A | Stock Option (right to buy) | 15,000 | 1.88 | 28.2K | 15,000 | — | ↗ |
| 2021-11-23 | PROEHL GERALD T | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 2.40 | 48.0K | 59,512 | — | ↗ |
| 2021-09-01 | Van Hoose Kyri K. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-17 | WIERENGA WENDELL | Director | C-Conversion | A | Common Stock | 8,163 | 0.00 | — | 13,041 | — | ↗ |
| 2021-08-17 | Scott Kathleen D. | Director | A-Award | A | Stock Option (right to Buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2021-08-17 | Sandler Andrew Seth | Director | A-Award | A | Stock Option (right to Buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2021-08-17 | Proehl Investment Ventures LLC | Director | C-Conversion | D | Series 1a Warrants | 573,750 | 0.00 | — | 0 | — | ↗ |
| 2021-08-17 | PROEHL GERALD T | Director / Officer / 10% Owner | C-Conversion | A | Common Stock | 361,147 | 0.00 | — | 1,278,464 | — | ↗ |
| 2021-08-17 | Nardo Christopher J. | Officer | C-Conversion | A | Common Stock | 2,439 | — | — | 2,439 | — | ↗ |
| 2021-08-17 | Mento Steven J | Director | A-Award | A | Stock Option (right to Buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2021-08-17 | INSLEY THOMAS | Officer | C-Conversion | A | Common Stock | 4,581 | — | — | 14,337 | — | ↗ |
| 2021-08-17 | HALE DAVID F | Director | C-Conversion | A | Common Stock | 12,195 | — | — | 311,606 | — | ↗ |
| 2021-08-17 | FISHER MARY | Director | A-Award | A | Stock Option (right to Buy) | 10,000 | 7.00 | 70.0K | 10,000 | — | ↗ |
| 2021-08-17 | Bedoya-Toro Munera Maria E | Officer | C-Conversion | A | Common Stock | 13,658 | — | — | 84,143 | — | ↗ |
| 2021-08-16 | PROEHL GERALD T | Officer | C-Conversion | A | Common Stock | 1,247,904 | — | — | 2,819,904 | — | ↗ |
| 2021-08-12 | WIERENGA WENDELL | Director | — | D | Common Stock | 0 | 0.00 | — | 4,878 | — | ↗ |
| 2021-08-12 | Scott Kathleen D. | Director | — | I | Common Stock | 0 | 0.00 | — | 2,439 | — | ↗ |
| 2021-08-12 | Sandler Andrew Seth | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-12 | Proehl Investment Ventures LLC | Director | — | D | Series 1a Warrants | 573,750 | 0.00 | — | 0 | — | ↗ |
| 2021-08-12 | PROEHL GERALD T | Officer / 10% Owner | — | D | Stock Option (Right to Buy) | 9,756 | 5.74 | 56.0K | 0 | — | ↗ |
| 2021-08-12 | Nardo Christopher J. | Officer | — | D | Common Stock | 0 | 0.00 | — | 25,121 | — | ↗ |
| 2021-08-12 | Mento Steven J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-12 | INSLEY THOMAS | Officer | — | I | Common Stock | 0 | 0.00 | — | 9,756 | — | ↗ |
| 2021-08-12 | HALE DAVID F | Director | — | I | Series 1a Warrants | 62,500 | 0.00 | — | 0 | — | ↗ |
| 2021-08-12 | FISHER MARY | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-12 | Bedoya-Toro Munera Maria E | Officer | — | I | Series 1a Warrants | 100,000 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
681.6K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher J. Nardo | Senior Vice President & Chief Development Officer | 513.8K | — |
| Kyri K. Van Hoose | Senior Vice President & Chief Financial Officer | 485.2K | female |
| Gerald T. Proehl | Founder, President, Chief Executive Officer & Chairman | 420.0K | male |
| David F. Hale | Co-Founder & Lead Independent Director | 73.0K | male |
| Maria Bedoya Toro Munera | Senior Vice President of Regulatory Affairs & Quality Assurance | 27.0K | — |
| Kyra Peckaitis | Vice President of Marketing | — | female |
| Sean Proehl | Associate General Counsel | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DRMA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
